Gallus BioPharmaceuticals has completed a second expansion of its Process Development (PD) facility at its headquarters in St. Louis, MO. This expansion provides additional laboratory space and state-of-the-art instrumentation to support Gallus’ growth.
Mark R. Bamforth, Gallus’ president and chief executive officer, commented, “Following the acquisition of the Laureate Biopharma business last September, Gallus is now supporting five of the top 15 pharmaceutical companies and a growing number of emerging and mid-sized biotechs in bringing new molecules to the clinic. This additional investment increases Gallus’ capacity to serve our clients’ needs with our team of more than 70 Process Development scientists. We’ve designed the new integrated PD labs to facilitate collaborative and efficient development and tech transfer of processes. The design allows our PD team flexibility in adjusting for project specific configurations as needed.”
The expansion includes the addition of the ambr™ System from TAP Biosystems, a high throughput system designed for microscale clone and media selection and bioreactor process optimization. This addition is in response to the rapidly growing need for optimizing the yields and purity of complex biotherapeutic molecules. Matt Caple, director of Cell Culture Development at Gallus, remarked, “The ambr™ high-throughput mini-bioreactor system allows Gallus to develop robust, high-producing cell culture processes for our clients while reducing time lines and meeting regulatory expectations.”